GlassScriptPhysician profile
Mark Howard Ellis
NPI 1568569424
$8,718.51
in general payments reported to CMS, 2019-2025
30 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,551 · 2020: $675 · 2021: $852 · 2022: $1,215 · 2023: $963 · 2024: $1,590 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,231.31 |
| Education | $193.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,557.56 | 2019-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $1,513.27 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,025.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $923.49 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $671.66 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Pfizer INC. | $444.44 | 2019-2024 | |
| Glaxosmithkline, LLC. | $392.05 | 2019-2024 | Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $363.51 | 2019-2025 | Xolair |
| Amgen INC. | $304.57 | 2021-2024 | Tezspire |
| Shire North American Group INC | $222.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.01 | 2019-2024 | |
| Optinose US, INC. | $162.76 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $119.15 | 2019-2021 | |
| Pharming Healthcare, INC. | $112.05 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $96.07 | 2025 | Neffy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $86.93 | 2024-2025 | Opzelura |
| Kaleo, INC. | $62.95 | 2023-2024 | Auvi-Q |
| Abbvie INC. | $59.59 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $58.12 | 2019 | |
| Octapharma USA, INC. | $53.06 | 2019-2022 | |
| Grifols USA, LLC | $52.42 | 2022-2025 | Xembify |
| Biocryst US Sales Co., LLC | $45.45 | 2022 | |
| Leo Pharma INC. | $42.73 | 2022 | |
| Horizon Therapeutics Plc | $41.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.39 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $34.40 | 2025 | |
| Azurity Pharmaceuticals, INC. | $27.58 | 2025 | Alvesco |
| Organon LLC | $21.43 | 2025 | Vtama |
| Hikma Pharmaceuticals USA | $20.75 | 2024 | Ryaltris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.